Search results for "Survival Analysis"

showing 10 items of 748 documents

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational …

2019

Abstract Background Regorafenib prolonged overall survival (OS) versus placebo in patients with treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an observational study of regorafenib for patients with mCRC in real-world clinical practice. Methods The international, prospective, CORRELATE study recruited patients with mCRC previously treated with approved therapies, for whom the decision to treat with regorafenib was made by the treating physician according to the local health authority approved label. The primary objective was safety, assessed by treatment-emergent adverse events (TEAEs; National Cancer Institute Common Terminology Criteria for Adve…

0301 basic medicineMaleCancer ResearchLung NeoplasmsColorectal cancerPyridinesGTP Phosphohydrolaseschemistry.chemical_compound0302 clinical medicineObservational studyProspective StudiesNeoplasm MetastasisFatiguePeritoneal NeoplasmsRegorafenibAged 80 and overLiver NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle AgedProgression-Free SurvivalOncology030220 oncology & carcinogenesisHypertensionFemaleHand-Foot SyndromeColorectal NeoplasmsAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyBone NeoplasmsPlaceboProto-Oncogene Proteins p21(ras)03 medical and health sciencesYoung AdultRegorafenibInternal medicinemedicineHumansAdverse effectSurvival analysisAgedAdverse effectsbusiness.industryPhenylurea CompoundsCarcinomaCancerMembrane ProteinsSurvival analysismedicine.disease030104 developmental biologychemistryObservational studyLymph NodesbusinessAdverse effects; Observational study; Regorafenib; Survival analysisEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

2016

Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).Methods:Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85 mg m -2, folinic acid 400 mg m -2, and 5-fluorouracil (400 mg m -2 bolus then 2400 mg m -2 over 46 h). Radiographic evaluation was performed every 8 weeks until progression. Primary endpoint was objective response rate.Results:Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8-77.6); complete response was observed in …

0301 basic medicineMaleCancer ResearchOrganoplatinum CompoundsLeucovorinPhases of clinical researchmedicine.disease_causeGastroenterology0302 clinical medicineadvanced colorectal cancerAntineoplastic Combined Chemotherapy ProtocolsClinical endpointNeoplasm MetastasisNecitumumabModified FOLFOX6Aged 80 and overnecitumumabAntibodies MonoclonalMiddle AgedOxaliplatinTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisFemaleKRASFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyEGFRNeutropeniamodified FOLFOX6Antibodies Monoclonal HumanizedDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciencesFolinic acidInternal medicinemedicineKRASHumansAdvanced colorectal cancerAgedbusiness.industrymedicine.diseaseSurvival AnalysisSurgeryOxaliplatinCancérologie030104 developmental biologyClinical StudybusinessNecitumumabBritish Journal of Cancer
researchProduct

Geographical variability in survival of European children with central nervous system tumours

2017

Survival for childhood central nervous system (CNS) tumours varies across Europe, partly because of the difficulty of distinguishing malignant from non-malignant disease. This study examines bias in CNS tumours survival analysis to obtain the reliable and comparable survival figures. We analysed survival data for about 15, 000 children (age <15) diagnosed with CNS between 2000 and 2007, from 71 population- based cancer registries in 27 countries. We selected high- quality data based on registry- specific data quality indicators and recorded observed 1-year and 5-year survival by countries and CNS entity. We provided age- adjusted survival and used a Cox model to calculate the hazard ratios …

0301 basic medicineMaleCancer ResearchPediatricsmedicine.medical_specialtyChildhood cancer survival Europe Population-based cancer registries Disparities Central nervous systemAdolescentPopulationPopulation-based cancer registrieSocio-culturaleDisparitiesCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineEpidemiology of cancerChildhood cancer survivalMedicineHumansPreschooleducationChildGrading (tumors)Survival rateSurvival analysiseducation.field_of_studybusiness.industryProportional hazards modelIncidenceHazard ratioCentral Nervous System NeoplasmInfantPopulation-based cancer registriesDisparitieSurvival AnalysisEurope030104 developmental biologyOncologyCentral nervous system030220 oncology & carcinogenesisChild PreschoolFemaleDeath certificateCentral nervous system; Childhood cancer survival; Disparities; Europe; Population-based cancer registries; Adolescent; Central Nervous System Neoplasms; Child; Child Preschool; Europe; Female; Humans; Incidence; Infant; Male; Survival Analysis; Oncology; Cancer ResearchbusinessHuman
researchProduct

Expression quantitative trait loci for PAX8 contributes to the prognosis of hepatocellular carcinoma

2017

Paired-box family member PAX8 encodes a transcription factor that has a role in cell differentiation and cell growth and may participate in the prognosis of hepatocellular carcinoma (HCC). By bioinformatics analysis, we identified several single nucleotide polymorphisms (SNPs) within a newly identified long non-coding RNA (lncRNA) AC016683.6 as expression quantitative trait loci (eQTLs) for PAX8. Hence, we hypothesized that PAX8eQTLs in lncRNA AC016683.6 may influence the HCC prognosis. We then performed a case-only study to assess the association between the two SNPs as well as the prognosis of HCC in 331 HBV-positive HCC patients without surgical treatment. Cox proportional hazard models …

0301 basic medicineMaleHeredityPaired BoxCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineMathematical and Statistical TechniquesMedicine and Health Scienceslcsh:ScienceMultidisciplinaryPharmaceuticsLiver DiseasesLiver NeoplasmsMiddle AgedPrognosisNucleic acidsSurvival RateGenetic MappingOncology030220 oncology & carcinogenesisHepatocellular carcinomaPhysical SciencesRegression AnalysisFemaleLiver cancerStatistics (Mathematics)Research ArticleCarcinoma HepatocellularGenotypeQuantitative Trait LociSingle-nucleotide polymorphismVariant GenotypesGastroenterology and HepatologyResearch and Analysis MethodsCarcinomasPolymorphism Single Nucleotide03 medical and health sciencesPAX8 Transcription FactorProtein DomainsDrug TherapyDiagnostic MedicineGastrointestinal TumorsCarcinomamedicineGeneticsChemotherapyHumansGenetic Predisposition to DiseaseAlleleStatistical MethodsNon-coding RNASurvival rateSurvival analysisAllelesbusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesProteinsHepatocellular Carcinomamedicine.disease030104 developmental biologyExpression quantitative trait lociCancer researchLong non-coding RNAsRNAlcsh:QbusinessMathematicsPLoS ONE
researchProduct

Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis.

2018

International audience; Objective: The aim of our study was to assess major cardiovascular event incidence, predictors, and mortality in ANCA-associated vasculitis (AAV).Methods: We conducted a retrospective cohort study of all GPA or MPA, according to Chapel Hill Consensus Conference classification criteria, diagnosed between 1981 and 2015. Major cardiovascular event was defined as acute coronary artery disease, or ischemic stroke, or peripheral vascular disease requiring a revascularization procedure. We calculated the comparative morbidity/mortality figure (CMF) and we used Cox proportional hazards regression models to assess the risk of coronary artery disease, ischemic stroke associate…

0301 basic medicineMaleRiskmedicine.medical_specialtyImmunologyPopulationMicroscopic PolyangiitisCoronary Artery DiseaseAntibodies Antineutrophil CytoplasmicCoronary artery diseaseCohort Studies03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIschemiaInternal medicineImmunology and AllergyMedicineHumanseducationStrokeAgedProportional Hazards ModelsRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studyIschemic strokebusiness.industryVascular diseaseIncidence (epidemiology)Mortality rateGranulomatosis with PolyangiitisRetrospective cohort studyMiddle Agedmedicine.diseaseSurvival Analysis3. Good healthStroke030104 developmental biologyAcute DiseaseCardiologyFemalebusinessGranulomatosis with polyangiitisANCA-Associated vasculitis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesJournal of autoimmunity
researchProduct

Recombinant human hepatocyte growth factor provides protective effects in cerulein-induced acute pancreatitis in mice.

2018

Acute pancreatitis is a multifactorial disease associated with profound changes of the pancreas induced by release of digestive enzymes that lead to increase in proinflammatory cytokine production, excessive tissue necrosis, edema, and bleeding. Elevated levels of hepatocyte growth factor (HGF) and its receptor c-Met have been observed in different chronic and acute pancreatic diseases including experimental models of acute pancreatitis. In the present study, we investigated the protective effects induced by the recombinant human HGF in a mouse model of cerulein-induced acute pancreatitis. Pancreatitis was induced by 8 hourly administrations of supramaximal cerulein injections (50 µg/kg, ip…

0301 basic medicineMalemedicine.medical_specialtyNecrosisPhysiologyClinical BiochemistryInflammationApoptosismedicine.disease_causeProtective AgentsAntioxidantsProinflammatory cytokine03 medical and health sciencesMiceInternal medicineEdemamedicineAnimalsHumansbusiness.industryHepatocyte Growth FactorCell BiologyProto-Oncogene Proteins c-metmedicine.diseaseGlutathioneSurvival AnalysisRecombinant ProteinsDisease Models AnimalOxidative Stress030104 developmental biologyEndocrinologyPancreatitisAcute pancreatitisPancreatitisHepatocyte growth factormedicine.symptombusinessOxidative stressCeruletidemedicine.drugSignal TransductionJournal of cellular physiology
researchProduct

EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors

2018

Abstract Glioblastoma (GBM) is a typically lethal type of brain tumor with a median survival of 15 months postdiagnosis. This negative prognosis prompted the exploration of alternative treatment options. In particular, the reliance of GBM on angiogenesis triggered the development of anti‐VEGF (vascular endothelial growth factor) blocking antibodies such as bevacizumab. Although its application in human GBM only increased progression‐free periods but did not improve overall survival, physicians and researchers still utilize this treatment option due to the lack of adequate alternatives. In an attempt to improve the efficacy of anti‐VEGF treatment, we explored the role of the egfl7 gene in ma…

0301 basic medicineMedicine (General)Vascular Biology & AngiogenesisAngiogenesisEndothelial Growth FactorsQH426-470chemistry.chemical_compoundangiogenesisMice0302 clinical medicineAntineoplastic Agents ImmunologicalResearch ArticlesCancerNeovascularization PathologicBrain NeoplasmsEndothelial stem cellVascular endothelial growth factormedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisendothelial cellMolecular MedicineHeterograftsEGFL7PericyteEGFL7medicine.drugResearch ArticleIntegrin alpha5beta1EGF Family of ProteinsintegrinBrain tumor03 medical and health sciencesR5-920GliomamedicineGeneticsHuman Umbilical Vein Endothelial CellsAnimalsHumansddc:610Cell ProliferationTemozolomidebusiness.industryCalcium-Binding ProteinsglioblastomaEndothelial Cellsmedicine.diseaseSurvival AnalysisDisease Models Animal030104 developmental biologychemistryCancer researchbusinessNeoplasm TransplantationNeuroscienceEMBO Molecular Medicine
researchProduct

Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study

2016

International audience; Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyStaphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsBacteremiaPenicillinsPrognostic factorsTertiary Care Centers03 medical and health sciencesInterquartile range[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinInternal medicineCase fatality ratemedicineHumansBlood cultureProspective StudiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedAntistaphylococcal penicillinsCross Infectionmedicine.diagnostic_testbusiness.industrySeptic shockGeneral MedicineMiddle AgedStaphylococcal Infectionsmedicine.diseasePrognosisSurvival Analysis3. Good healthSurgeryInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinBacteraemiaAntistaphylococcal penicillinFemaleFrancebusinessmedicine.drug
researchProduct

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-03…

2017

Abstract Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) plus bevacizumab in patients with RAS-mutant tumours needs to be further evaluated. Whether to treat patients with BRAF-mutant tumours with either bevacizumab or anti-epidermal growth factor receptor (EGFR) antibodies remains unclear. Methods Patients treated within the FIRE-3 trial were retrospectively tested for BRAF and RAS mutations using formalin fixated paraffin embedded (FFPE) tumour material applying pyrosequencing for KRAS and NRAS exon 2, 3 and 4 mutations as far as for BRAF mutations. Survival …

0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologyMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinCetuximabmedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansneoplasmsSurvival analysisAgedRetrospective StudiesCetuximabbusiness.industryLiver NeoplasmsExonsMiddle Agedmedicine.diseasedigestive system diseasesIrinotecanBevacizumab030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisMutationFOLFIRICamptothecinFemaleKRASFluorouracilbusinessColorectal Neoplasmsmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

2017

The immunomodulatory role of human leukocyte antigen (HLA)-E in hematopoietic stem cell transplantation (HSCT) has not been extensively investigated. To this end, we genotyped 509 10/10 HLA unrelated transplant pairs for HLA-E, in order to study the effect of HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome in an acute leukemia (AL) setting. Overall survival (OS), disease free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were set as endpoints. Analysis of our data revealed a significant correlation between HLA-E mismatch and improved HSCT outcome, as shown by both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate (hazard ratio (HR)…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentGenotypemedicine.medical_treatment610Hematopoietic stem cell transplantationHuman leukocyte antigen600 Technik Medizin angewandte Wissenschaften::610 Medizin und GesundheitArticle03 medical and health sciencesYoung Adult0302 clinical medicineCell Therapy & ImmunotherapyInternal medicineMedicineHumansTransplantation Homologousddc:610Potassium Channels Inwardly RectifyingSurvival analysisAllelesAgedBone Marrow TransplantationAcute leukemiabusiness.industryDonor selectionHistocompatibility TestingHazard ratioHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisTransplantationLeukemiaLeukemia Myeloid Acute030104 developmental biologyTreatment OutcomeImmunologyFemalebusiness030215 immunology
researchProduct